Daiichi Sankyo Plans Growth In Mid-term Management Plan Despite Olmetec Patent Expiry
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo President Joji Nakayama announced at a medium term management plan briefing March 22 that the company aims to grow 4% a year in the Japanese market between 2013 and 2017, hoping to reach sales revenues of ¥630 billion in 2017.